| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 47,715 | 47,760 | 20:16 | |
| 47,695 | 47,740 | 20:16 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19:46 | Novo Nordisk Turns to Self-Replicating RNA Startup to Discover New Metabolic Medicines | ||
| 18:58 | Novo reels in Replicate for new cardiometabolic drugs | ||
| 18:46 | Novo Nordisk enlists srRNA developer Replicate in $550m deal | ||
| 17:15 | FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk | ||
| 16:46 | Novo strikes RNA drug deal with startup Replicate |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15:59 | TEVA Trumpets Saxenda, Stocks Eke Higher | ||
| 15:42 | Teva stock rises on launch of first generic weight loss GLP-1 drug | ||
| 15:24 | Teva gets FDA nod for generic version of Novo's weight loss drug | ||
| 15:18 | Teva Announces FDA Approval And U.S. Launch Of Generic Saxenda | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Thursday said that the U.S. Food and Drug Administration (FDA) has approved... ► Artikel lesen | |
| 14:34 | Teva Pharmaceutical Industries Ltd: Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) - First Generic GLP-1 Indicated for Weight Loss | Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.This approval and launch add to Teva's continued... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| NOVO NORDISK A/S | 47,695 | -1,57 % |
| TEVA PHARMACEUTICAL INDUSTRIES LTD | 15,450 | -0,64 % |
